Should I buy or sell Sutro Biopharma stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" STRO shares. View STRO analyst ratings or view top-rated stocks .

What is Sutro Biopharma's stock price target for 2024?

8 brokers have issued 1-year price objectives for Sutro Biopharma's stock. Their STRO share price targets range from $8.00 to $25.00. On average, they anticipate the company's share price to reach $14.00 in the next twelve months. This suggests a possible upside of 387.8% from the stock's current price. View analysts price targets for STRO or view top-rated stocks among Wall Street analysts .

How have STRO shares performed in 2023?

Sutro Biopharma's stock was trading at $8.08 on January 1st, 2023. Since then, STRO shares have decreased by 64.5% and is now trading at $2.87. View the best growth stocks for 2023 here .

When is Sutro Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our STRO earnings forecast .

How were Sutro Biopharma's earnings last quarter?

Sutro Biopharma, Inc. (NASDAQ:STRO) announced its earnings results on Monday, November, 13th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by $0.05. Sutro Biopharma had a negative net margin of 354.53% and a negative trailing twelve-month return on equity of 99.73%.

What ETF holds Sutro Biopharma's stock ?

Simplify Propel Opportunities ETF holds 120,000 shares of STRO stock, representing 0.53% of its portfolio.

What is William J. Newell's approval rating as Sutro Biopharma's CEO?

11 employees have rated Sutro Biopharma Chief Executive Officer William J. Newell on Glassdoor.com . William J. Newell has an approval rating of 100% among the company's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sutro Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Pfizer (PFE) , VBI Vaccines (VBIV) , Aldeyra Therapeutics (ALDX) , Dynavax Technologies (DVAX) , Fulcrum Therapeutics (FULC) , IDEAYA Biosciences (IDYA) , Provention Bio (PRVB) , Sorrento Therapeutics (SRNE) , Xeris Biopharma (XERS) and AbbVie (ABBV) .

When did Sutro Biopharma IPO?

(STRO) raised $75 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Sutro Biopharma's major shareholders?

Sutro Biopharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Rubric Capital Management LP (5.53%), Adage Capital Partners GP L.L.C. (5.13%), Kynam Capital Management LP (2.57%), Acadian Asset Management LLC (1.28%), Vontobel Holding Ltd. (0.74%) and Sectoral Asset Management Inc. (0.71%). Insiders that own company stock include Brunilda Shtylla, Nicki Vasquez , Trevor Hallam and William J Newell. View institutional ownership trends .

How do I buy shares of Sutro Biopharma?

Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Sutro Biopharma Stock Price, News & Analysis (NASDAQ:STRO)

$2.87

+0.12 (+4.36%)

(As of 12/4/2023 ET)

Compare

Today's Range: $2.69
▼
$2.88
50-Day Range: $2.07
▼
$3.98
52-Week Range: $2.01
▼
$8.72

Volume: 567,596 shs
Average Volume: 522,511 shs
Market Capitalization: $174.93 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.00

Sutro Biopharma MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.88 Rating Score
Upside/Downside: 387.8% Upside
$14.00 Price Target
Short Interest: Healthy
3.77% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.70
Upright™ Environmental Score
News Sentiment: 0.97
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($3.03) to ($3.23) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.76 out of 5 stars

Medical Sector

68th out of 952 stocks

Biological Products, Except Diagnostic Industry

10th out of 155 stocks

4.4

Analyst's Opinion

Consensus Rating
Sutro Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.00, Sutro Biopharma has a forecasted upside of 387.8% from its current price of $2.87.
Amount of Analyst Coverage
Sutro Biopharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

4.0

Short Interest

Percentage of Shares Shorted
3.77% of the outstanding shares of Sutro Biopharma have been sold short.
Short Interest Ratio / Days to Cover
Sutro Biopharma has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Sutro Biopharma has recently decreased by 2.95%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Sutro Biopharma does not currently pay a dividend.
Dividend Growth
Sutro Biopharma does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Sutro Biopharma has received a 73.67% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Sutro Biopharma is -0.70.

2.8

News and Social Media Coverage

News Sentiment
Sutro Biopharma has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Sutro Biopharma this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for STRO on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sutro Biopharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.90% of the stock of Sutro Biopharma is held by insiders.
Percentage Held by Institutions
89.40% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Sutro Biopharma are expected to decrease in the coming year, from ($3.03) to ($3.23) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sutro Biopharma is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sutro Biopharma is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sutro Biopharma has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Sutro Biopharma Stock (NASDAQ:STRO)

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. Its pre-clinical product candidate STRO-003, a ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

STRO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

STRO Stock News Headlines

December 4, 2023 | finance.yahoo.com

Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

December 1, 2023 | seekingalpha.com

AbbVie-ImmunoGen buyout deal lifts ADC-focused biotechs

December 4, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

December 1, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: G1 Therapeutics (GTHX), Sutro Biopharma (STRO)

November 27, 2023 | markets.businessinsider.com

Vaxcyte Obtains Control Over Manufacturing & Development Of Cell-Free Extract For Vaccine Candidates

November 27, 2023 | finance.yahoo.com

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates

November 23, 2023 | finanznachrichten.de

Sutro Biopharma, Inc.: Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

November 21, 2023 | finance.yahoo.com

Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

December 4, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 16, 2023 | markets.businessinsider.com

Optimistic Outlook on Sutro Biopharma: Solid Financials, Promising Drug Pipeline, and High Return Potential Fuel Buy Rating

November 15, 2023 | finanznachrichten.de

Sutro Biopharma, Inc.: Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

November 15, 2023 | markets.businessinsider.com

Expert Ratings for Sutro Biopharma

November 13, 2023 | finance.yahoo.com

Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

November 13, 2023 | finance.yahoo.com

Sutro Biopharma Inc (STRO) Reports Q3 2023 Financial Results and Business Updates

November 11, 2023 | benzinga.com

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sutro Biopharma, Inc. (NASDAQ: STRO) and Encourages Investors to Contact the Firm

November 9, 2023 | msn.com

Deutsche Bank Initiates Coverage of Sutro Biopharma (STRO) with Buy Recommendation

November 8, 2023 | news.yahoo.com

Sutro introduces AI-powered app creation with no coding required

November 6, 2023 | morningstar.com

Sutro Biopharma Inc STRO

November 4, 2023 | finance.yahoo.com

Sutro Biopharma (NASDAQ:STRO) shareholders are up 11% this past week, but still in the red over the last three years

October 25, 2023 | markets.businessinsider.com

Oppenheimer Reaffirms Their Buy Rating on Sutro Biopharma (STRO)

October 24, 2023 | markets.businessinsider.com

Promising Clinical Trials and Robust Financial Health Drive Buy Rating for Sutro Biopharma

October 24, 2023 | msn.com

Wedbush Reiterates Sutro Biopharma (STRO) Outperform Recommendation

October 22, 2023 | finance.yahoo.com

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023

October 16, 2023 | finance.yahoo.com

Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference

October 7, 2023 | msn.com

Oppenheimer Initiates Coverage of Sutro Biopharma (STRO) with Outperform Recommendation

October 6, 2023 | markets.businessinsider.com

5 Analysts Have This to Say About Sutro Biopharma

October 1, 2023 | barrons.com

Sutro Biopharma Inc.

See More Headlines

Receive STRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 12/04/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 4/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:STRO
CUSIP: N/A
CIK: 1382101
Web: www.sutrobio.com
Phone: (650) 392-8412
Fax: N/A
Employees: 298
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $14.00
High Stock Price Target: $25.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +387.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.88
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.91)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-119,200,000.00
Net Margins: -354.53%
Pretax Margin: -349.63%
Return on Equity: -99.73%
Return on Assets: -40.19%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.18
Quick Ratio: 5.18

Sales & Book Value

Annual Sales: $67.77 million
Price / Sales: 2.58
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.78 per share
Price / Book: 0.76

Miscellaneous

Outstanding Shares: 60,950,000
Free Float: 56,747,000
Market Cap: $174.93 million
Optionable: Not Optionable
Beta: 0.86

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. William J. Newell J.D. (Age 65)
CEO & Director
Comp: $1.07M
Ms. Jane Chung R.Ph. (Age 52)
Chief Commercial Officer
Comp: $934.64k
Dr. James R. Swartz Ph.D.
Sc.D., Founder
Mr. Edward C. Albini (Age 65)
CFO & Secretary
Comp: $596.4k
Dr. Venkatesh Srinivasan Ph.d.
Chief Technical Operations Officer
Dr. Hans-Peter Gerber Ph.D.
Chief Scientific Officer
Mr. David Pauling J.D.
M.A., General Counsel
Ms. Linda A. Fitzpatrick (Age 66)
Chief People & Communications Officer
Comp: $595.79k
Dr. Nicki Vasquez Ph.D. (Age 60)
Chief Portfolio Strategy & Alliance Officer
Ms. Brunilda Shtylla M.B.A. (Age 49)
M.S., Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

STRO Stock Analysis - Frequently Asked Questions

Should I buy or sell Sutro Biopharma stock right now?: 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" STRO shares.
View STRO analyst ratings or view top-rated stocks.
What is Sutro Biopharma's stock price target for 2024?: 8 brokers have issued 1-year price objectives for Sutro Biopharma's stock. Their STRO share price targets range from $8.00 to $25.00. On average, they anticipate the company's share price to reach $14.00 in the next twelve months. This suggests a possible upside of 387.8% from the stock's current price.
View analysts price targets for STRO or view top-rated stocks among Wall Street analysts.
How have STRO shares performed in 2023?: Sutro Biopharma's stock was trading at $8.08 on January 1st, 2023. Since then, STRO shares have decreased by 64.5% and is now trading at $2.87.
View the best growth stocks for 2023 here.
When is Sutro Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our STRO earnings forecast.
How were Sutro Biopharma's earnings last quarter?: Sutro Biopharma, Inc. (NASDAQ:STRO) announced its earnings results on Monday, November, 13th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by $0.05. Sutro Biopharma had a negative net margin of 354.53% and a negative trailing twelve-month return on equity of 99.73%.
What ETF holds Sutro Biopharma's stock ?: Simplify Propel Opportunities ETF holds 120,000 shares of STRO stock, representing 0.53% of its portfolio.

What is William J. Newell's approval rating as Sutro Biopharma's CEO?: 11 employees have rated Sutro Biopharma Chief Executive Officer William J. Newell on Glassdoor.com. William J. Newell has an approval rating of 100% among the company's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Sutro Biopharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Pfizer (PFE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), IDEAYA Biosciences (IDYA), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), Xeris Biopharma (XERS) and AbbVie (ABBV).
When did Sutro Biopharma IPO?: (STRO) raised $75 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who are Sutro Biopharma's major shareholders?: Sutro Biopharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Rubric Capital Management LP (5.53%), Adage Capital Partners GP L.L.C. (5.13%), Kynam Capital Management LP (2.57%), Acadian Asset Management LLC (1.28%), Vontobel Holding Ltd. (0.74%) and Sectoral Asset Management Inc. (0.71%). Insiders that own company stock include Brunilda Shtylla, Nicki Vasquez, Trevor Hallam and William J Newell.
View institutional ownership trends.
How do I buy shares of Sutro Biopharma?: Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:STRO) was last updated on 12/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial